Triple-negative breast cancer: new perspectives for novel therapies
- 4 July 2013
- journal article
- review article
- Published by Springer Nature in Medical Oncology
- Vol. 30 (3) , 1-6
Abstract
Triple-negative breast cancer (TNBC) represents 10–20 % of all mammary tumors. It is often found in younger women and has been associated with poor prognosis, due to aggressive tumor phenotype(s), early metastasis to visceral organ or brain after chemotherapy and present lack of clinically established targeted therapies. In recent years, a greater understanding of the biology of this disease has led to the development of numerous and varied therapeutic approaches, especially the trials on poly (ADP-ribose) polymerase inhibitors BSI-201 and olaparib, and antiangiogenic agents such as bevacizumab and sunitinib, which have raised hopes in the treatment for TNBC and BRCA1/2-positive disease. But should these trials fail, what are the new possible perspectives we have in our hand to fight this disease? In the current review, we will assess mainly the possible future targeted therapeutic strategies, which could be the answer to our question in TNBC. Recent studies have shown several markers, which have roles in TNBC that could be possible targets for therapy. Some of these markers are p53-induced miR-205, leptin receptor antagonist peptide, enhancer of zeste homolog 2 and Notch 1 pathway components, each of them could offer different mechanism for target therapy in TNBC. Last but not least, vaccinia virus GLV-1h153 has shown exciting result in treating and preventing metastatic triple-negative breast cancer.Keywords
This publication has 52 references indexed in Scilit:
- Treatment of breast cancer stem cells with oncolytic herpes simplex virusCancer Gene Therapy, 2012
- Oncosuppressive role of p53‐induced miR‐205 in triple negative breast cancerMolecular Oncology, 2012
- 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1Breast Cancer Research and Treatment, 2012
- Prevalence and Prognostic Role of Triple-Negative Breast Cancer by Race: A Surveillance StudyClinical Breast Cancer, 2011
- Coordinated Regulation of Polycomb Group Complexes through microRNAs in CancerCancer Cell, 2011
- EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin SignalingCancer Cell, 2011
- Regulation of Tumor Angiogenesis by EZH2Cancer Cell, 2010
- ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approachesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast TumorsCancer Research, 2009
- Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1Oncogene, 2008